XSHG
603658
Market cap2.84bUSD
Oct 09, Last price
33.45CNY
1D
0.72%
1Q
8.67%
Jan 2017
-39.83%
IPO
44.81%
Name
Autobio Diagnostics Co Ltd
Chart & performance
P/E
17.90
P/S
4.52
EPS
1.87
Div yield, %
3.79%
Shrs. gr., 5y
0.46%
Rev. gr., 5y
7.25%
Revenues
4.23b
-5.47%
Net income
1.07b
-10.59%
CFO
1.34b
+2.47%
Dividend
Jun 01, 20261.31 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
Key people
Yongjun Miao
Chairman of the Board · since 2012
Zengli Yang
General Manager, Director · since 2012
Ruikuan Fang
Deputy General Manager, Secretary of the Board · since 2012
Chaojie Feng
Chief Financial Officer, Deputy General Manager, Director · since 2012
Xuewei Wu
Deputy General Manager, Director · since 2012
Ruifeng Zhang
Executive Deputy General Manager, Director · since 2024
Guangyu Fu
Executive Deputy General Manager, Director · since 2012
Yaxun Zhang
Vice Chairman of the Board · since 2012
Yuanming Qi
Independent Director · since 2024
Hailing Qiao
Independent Director · since 2025
Independent Director · since 2024
Independent Director · since 2024
Headquarters & legal address
郑州经济技术开发区经北一路87号
郑州市, HA 450000
CN
郑州市, HA 450000
CN
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||